Who are Norepinephrine + Ascorbic Acid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Normal saline with epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-ascorbic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Norepinephrine + Ascorbic Acid — Competitive Intelligence Brief

Norepinephrine + Ascorbic Acid (Norepinephrine + Ascorbic Acid) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Vasopressor. Area: Cardiovascular / Critical Care.

marketed Sympathomimetic amine / Vasopressor Alpha-1, alpha-2, and beta-1 adrenergic receptors Cardiovascular / Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine + Ascorbic Acid (Norepinephrine + Ascorbic Acid) — The University of Texas at Arlington. Norepinephrine acts as a sympathomimetic agent to increase blood pressure and cardiac output, while ascorbic acid (vitamin C) may enhance catecholamine stability and provide antioxidant support.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norepinephrine + Ascorbic Acid TARGET	Norepinephrine + Ascorbic Acid	The University of Texas at Arlington	marketed	Sympathomimetic amine / Vasopressor	Alpha-1, alpha-2, and beta-1 adrenergic receptors
Normal saline with epinephrine	Normal saline with epinephrine	West Penn Allegheny Health System	marketed	Sympathomimetic amine / Vasopressor	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Vasopressor class)

The University of Texas at Arlington · 1 drug in this class
West Penn Allegheny Health System · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine + Ascorbic Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-ascorbic-acid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab